TRENDING TOPICS AND NEWS IN HCT AND CELLULAR THERAPY

An innovative high-throughput platform that allows important T cell receptors (TCRs) to be cloned at a rapid pace could help scientists better understand the mechanics of minor histocompatibility...

Owing to its consistent presence in B-cell lymphomas and leukemias, researchers tout CD22's promise as a therapeutic target, but they suspect chimeric antigen receptor (CAR) immunotherapy may...

Reduced-intensity conditioning with treosulfan and fludarabine before allogeneic hematopoietic cell transplantation (allo-HCT) is safe and effective, a real-world analysis affirms. Researchers...

Based on a study of the youngest allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients, the myeloablative conditioning regimen BuCy (bulsulfan and cyclophosphamide) is more...

Data gleaned from preclinical models support glypican 2 (GPC2) as a viable target for chimeric antigen receptor (CAR) T-cell therapy in the setting of neuroblastoma and small cell lung cancer.

Researchers have developed a neutralizing antibody with the potential to improve quality-of-life and survival outcomes in patients with immune-driven fibrotic skin conditions. EREG, a DC3...